Safety considerations for an Rx to OTC Switch Program

Duration: 51 minutes


Registration

If you do not wish to receive any communication from us, you may unsubscribe at any time. Click here to view our privacy policy.


Why watch

Key Learnings

  •  Understand how safety considerations affect the many aspects of an Rx-to-OTC switch program
  •  Integrate FDA’s principal safety concerns into a switch submission
  •  Understand how analyses are conducted to support a product’s safety  
  •  Examine how these elements apply in a case study
speakers

A full day of inspirational speakers

Proud to bring inspirational speakers from across the globe. 



Bao-Anh Nguyen-Khoa

Senior Manager, Pharmacovigilance, Epidemiology & Risk Management (PER-EPI), PharmaLex US Corporation

Bao is a licensed clinical pharmacist with Doctor of Pharmacy (with a residency in Drug Information) and Master of Public Health degrees. He joined PharmaLex (via The Degge Group, Ltd.) in 2003 and is currently a Senior Research Manager with the pharmacoepidemiology and drug safety group (PER-EPI).